ARTICLE | Company News
Janssen, Locus partner on CRISPR-Cas3 bacteriophages
January 4, 2019 1:11 AM UTC
Janssen Pharmaceuticals Inc. partnered with Locus Biosciences Inc. (Morrisville, N.C.) to develop and commercialize CRISPR-Cas3-enhanced bacteriophage therapies against two bacterial pathogens to treat infections of the respiratory tract and other organ systems.
Locus will receive $20 million up front and is eligible for up to $798 million in milestones, plus royalties...
BCIQ Target Profiles